Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Kala Pharmaceuticals stock
Learn how to easily invest in Kala Pharmaceuticals stock.
Kala Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Kala Pharmaceuticals shares (KALA) are listed on the NASDAQ and all prices are listed in US Dollars. Kala Pharmaceuticals employs 188 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Kala Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KALA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Kala Pharmaceuticals stock price (NASDAQ: KALA)Use our graph to track the performance of KALA stocks over time.
Kala Pharmaceuticals shares at a glance
|Latest market close||$1.04|
|52-week range||$1.01 - $9.97|
|50-day moving average||$1.67|
|200-day moving average||$3.85|
|Wall St. target price||$6.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.03|
Buy Kala Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kala Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kala Pharmaceuticals price performance over time
|1 week (2022-01-10)||-1.89%|
|1 month (2021-12-17)||-25.71%|
|3 months (2021-10-15)||-52.94%|
|6 months (2021-07-16)||-72.63%|
|1 year (2021-01-15)||-86.11%|
|2 years (2020-01-17)||-84.05%|
|3 years (2019-01-17)||5.78|
|5 years (2017-01-13)||N/A|
Kala Pharmaceuticals financials
|Revenue TTM||$11.6 million|
|Gross profit TTM||$4.2 million|
|Return on assets TTM||-33.25%|
|Return on equity TTM||-150.63%|
|Market capitalisation||$69.4 million|
TTM: trailing 12 months
Kala Pharmaceuticals share dividends
We're not expecting Kala Pharmaceuticals to pay a dividend over the next 12 months.
Kala Pharmaceuticals share price volatility
Over the last 12 months, Kala Pharmaceuticals's shares have ranged in value from as little as $1.01 up to $9.969. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kala Pharmaceuticals's is 0.2142. This would suggest that Kala Pharmaceuticals's shares are less volatile than average (for this exchange).
Kala Pharmaceuticals overview
Kala Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009.
Kala Pharmaceuticals in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Kala Pharmaceuticals Inc Shares Close in on 52-Week Low - Market Mover
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Kala Pharmaceuticals is owned by insiders or institutions?
Currently 0.992% of Kala Pharmaceuticals shares are held by insiders and 51.199% by institutions. How many people work for Kala Pharmaceuticals?
Latest data suggests 188 work at Kala Pharmaceuticals. When does the fiscal year end for Kala Pharmaceuticals?
Kala Pharmaceuticals's fiscal year ends in December. Where is Kala Pharmaceuticals based?
Kala Pharmaceuticals's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is Kala Pharmaceuticals's ISIN number?
Kala Pharmaceuticals's international securities identification number is: US4831191030 What is Kala Pharmaceuticals's CUSIP number?
Kala Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 483119103
More guides on Finder
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
Ask an Expert